Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJBOCR)

Drug Name
Levacecarnine hci Drug Info
Synonyms
Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine; Nicetile (TN); L-Carnitine
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Approved [1]
Medium chain acyl-CoA dehydrogenase deficiency Approved [2]
Nutritional deficiency 5B50-5B71 Approved [3]
Postpoliomyelitis syndrome Approved [2]
Ulcerative colitis DD71 Approved [2]
Cross-matching ID
PubChem CID
10917
ChEBI ID
CHEBI:16347
CAS Number
CAS 541-15-1
TTD Drug ID
DMJBOCR
VARIDT Drug ID
DR00255
INTEDE Drug ID
DR0936
ACDINA Drug ID
D00359

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Carnitine O-palmitoyltransferase I (CPT1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Perhexiline DMINO7Z Angina pectoris BA40 Approved [16]
SDZ-CPI-975 DM70MJQ Diabetic complication 5A2Y Discontinued in Phase 1 [17]
Etomoxir DM3BHN1 Heart failure BD10-BD13 Terminated [18]
DB-200 DMTXPSB Psoriasis vulgaris EA90 Terminated [19]
C75 DMHGX1N Obesity 5B81 Investigative [20]
Drug(s) Transported By Organic cation/carnitine transporter 2 (SLC22A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [21]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [22]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [23]
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [24]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [25]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [26]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [26]
Mepyramine DMB4SFH Allergic rhinitis CA08.0 Approved [27]
Acetylcarnitine DM4UE3K Chronic fatigue syndrome 8E49 Phase 4 [28]
acetyl-L-carnitine DM74HGJ Discovery agent N.A. Investigative [22]
Verapamil DMA7PEW Angina pectoris BA40 Approved [52]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [55]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [58]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [59]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Arsenic DMTL2Y1 N. A. N. A. Approved [61]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Transported By Monocarboxylate transporter 9 (SLC16A9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
uric acid DMA1MKT Discovery agent N.A. Investigative [29]
Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Genital herpes 1A94 Approved [30]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [30]
Glycine DMIOZ29 Allergic rhinitis CA08.0 Approved [31]
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [32]
Valaciclovir DMHKS94 Genital herpes 1A94 Approved [33]
Valganciclovir DMS2IUH Virus infection 1A24-1D9Z Approved [34]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [35]
D-Serine DM3YH4I N. A. N. A. Phase 4 [36]
L-threonine DMFHTBX Discovery agent N.A. Investigative [36]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Transported By Fly-like putative transporter 2 (SLC22A16)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Drug(s) Transported By Organic cation/carnitine transporter 1 (SLC22A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [38]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [38]
Cytarabine DMZD5QR Acute lymphoblastic leukaemia 2A85 Approved [39]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [40]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [26]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [41]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic Acid DMEMBJC Colorectal carcinoma Approved [42]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [43]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [44]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [45]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [46]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [47]
Verapamil DMA7PEW Angina pectoris BA40 Approved [48]
Estrone DM5T6US Acne vulgaris ED80 Approved [49]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [50]
Ethanol DMDRQZU Chronic pain MG30 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 4 (SLC22A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [62]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [55]
Leflunomide DMR8ONJ Arthritis FA20 Approved [64]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [66]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [67]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [59]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Gamma-butyrobetaine dioxygenase (BBOX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [13]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [69]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [13]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [66]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [70]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [71]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [72]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carnitine O-palmitoyltransferase I (CPT1B) TTDL0NY CPT1B_HUMAN Activator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Carnitine/acylcarnitine translocase (SLC25A20) DTQOUM4 MCAT_HUMAN Substrate [5]
Monocarboxylate transporter 9 (SLC16A9) DTQK5O9 MOT9_HUMAN Substrate [6]
Fly-like putative transporter 2 (SLC22A16) DTPATLS S22AG_HUMAN Substrate [7]
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) DTW7AE3 AAAT_HUMAN Substrate [8]
Organic cation/carnitine transporter 1 (SLC22A4) DT2EG60 S22A4_HUMAN Substrate [9]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [11]
Carnitine O-acetyltransferase (CRAT) DEIGQCY CACP_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Gamma-butyrobetaine dioxygenase (BBOX1) OTKEX4RK BODG_HUMAN Biotransformations [13]
Organic cation/carnitine transporter 2 (SLC22A5) OTC36TYB S22A5_HUMAN Gene/Protein Processing [14]
Solute carrier family 22 member 4 (SLC22A4) OT4LOVI9 S22A4_HUMAN Regulation of Drug Effects [15]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4780).
4 Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
5 Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004 Oct;24(4):312-20.
6 Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney. BMC Neurosci. 2016 Jul 1;17(1):43.
7 The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
8 A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
9 Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
10 Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
11 Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. Biol Pharm Bull. 1993 Dec;16(12):1240-3.
12 Structural and mutational characterization of L-carnitine binding to human carnitine acetyltransferase. J Struct Biol. 2004 Jun;146(3):416-24.
13 The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. Toxicol Lett. 2011 Jun 24;203(3):219-26. doi: 10.1016/j.toxlet.2011.03.019. Epub 2011 Mar 23.
14 Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicol Appl Pharmacol. 2019 Jan 15;363:47-56. doi: 10.1016/j.taap.2018.11.007. Epub 2018 Nov 19.
15 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
16 Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
17 Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
18 Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
19 Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.
20 C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
21 Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
22 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
23 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
24 Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
25 Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
26 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
27 Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
28 Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
29 Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. Hum Cell. 2013 Dec;26(4):133-6.
30 Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
31 Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
32 High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
33 Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
34 Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
35 Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
36 D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
37 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
38 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
39 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
40 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
41 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
42 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
43 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
44 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
45 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
46 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
47 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
50 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
51 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
52 Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos. 2005 Jan;33(1):31-7. doi: 10.1124/dmd.104.001560. Epub 2004 Oct 14.
53 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
54 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
55 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
56 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
57 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
58 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
59 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
60 Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant. 2010 Feb;25(2):426-33. doi: 10.1093/ndt/gfp456. Epub 2009 Sep 7.
61 Inorganic arsenic as an endocrine disruptor: modulation of the glucocorticoid receptor pathway in placental cells via CpG methylation. Chem Res Toxicol. 2019 Mar 18;32(3):493-499.
62 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
63 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
64 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
65 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
66 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
67 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
68 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
69 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
70 Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
71 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
72 Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.